Headquartered in Winston-Salem, ProKidney leases an undetermined amount of space at the general-industrial-zoned building at ...
It is unclear what will happen to ProKidney's plans for a $458-million, 330-job commercial manufacturing facility in ...
The fate is uncertain for a proposed high-profile ProKidney Corp. manufacturing plant in Greensboro after the Winston-Salem ...
WFMY News2 on MSN12h
ProKidney no longer coming to Greensboro, Chamber of Commerce confirmsGREENSBORO, N.C. — Biotech company ProKidney will no longer be coming to Greensboro, according to the City of Greensboro ...
ProKidney, which works to treat chronic kidney disease, had previously announced plans to expand its operation into ...
ProKidney's REACT® therapy shows kidney function stabilization. Find out why PROK stock is risky due to cash issues and ...
Prokidney Corp. ( (PROK) ) has released its Q3 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.
FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...
Judah Frommer, an analyst from Morgan Stanley, maintained the Hold rating on ProKidney (PROK – Research Report). The associated price target remains the same with $3.00. Judah Frommer has given his ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback